SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders anticipate the CPI release, with community members discussing potential market reactions and hedging strategies. Talk of terminated trade negotiations with Canada and their potential impact are circulating. Overall market sentiment seems cautiously bullish, with some bracing for volatility.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

$AVNT is trending as the community discusses its recent price action and potential.  Traders are actively debating its volatility, entry points, and whether it can sustain its upward momentum.  Some believe its association with Coinbase and its position as a perp dex could drive future growth.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending due to a lowered Q1 revenue outlook, despite reaffirming strong full-year guidance and highlighting over $12 billion in new design wins for Q2 delivery. While some investors express frustration with management's forecasting, others view the dip as a buying opportunity, citing robust demand for AI solutions and confidence in long-term growth. Community discussions center on the significance of the delayed revenue and the potential for a rebound driven by strong Q2 performance.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

B All In ($BALLIN) is gaining attention, with community members highlighting its availability on Phantom Wallet and touting potential gains. The conversation centers around the idea of a "balling" lifestyle and the opportunity for early entry. However, some users are also expressing skepticism, labeling it a scam.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid discussions about potential market manipulation and its seemingly unstoppable upward momentum, with community members debating whether a pullback is due. Speculation is high around upcoming CPI data and its potential impact, while some traders point to a disconnect between market performance and underlying fundamentals. Talk of a Trump-Xi meeting is also influencing sentiment.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around ongoing development and utilities, including staking and play-to-earn games, while highlighting its resilience as a long-term project. Community members are excited about upcoming burns and the potential for significant growth. The focus remains on building a strong foundation and achieving new all-time highs.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. It also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment offers products and services sold for applications within the data center, communication networks, and commercial and industrial markets in North America and Latin America. The Asia Pacific segment includes products and services sold for applications within the data center, communication networks, and commercial or industrial markets throughout Greater China, Australia and New Zealand, Southeast Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Columbus, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv is trending due to a combination of strong Q3 earnings, raised guidance, and positive analyst ratings, all driven by the increasing demand for AI infrastructure and data centers. The community is discussing the company's growth potential, strategic acquisitions, and its partnership with NVIDIA. Some investors express frustration with price action, while others remain bullish on the long-term prospects of Vertiv in the AI space.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following its latest earnings report, which beat expectations and highlighted the company's focus on AI and foundry services. The community is discussing the potential for a significant rise, with some targeting $50 and beyond, driven by renewed confidence in Intel's growth prospects. Investors are also considering Intel's strategic importance and the impact of government support for domestic semiconductor manufacturing.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF ($DIA) is trending due to renewed US-China trade tensions following President Trump's threat of increased tariffs, sparking market volatility and a sell-off. Community discussions revolve around the potential economic impact and whether this is a buying opportunity or the start of a larger correction. Investors are also monitoring upcoming earnings reports and potential shifts in Federal Reserve policy in response to these developments.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

Li Auto is trending as investors discuss the company's expansion plans amid sales declines and increasing competition in the Chinese market. Community members are weighing the potential of its product portfolio and management against concerns about sales and expansion outside of mainland China. Some are highlighting potential support levels and accumulation strategies while others point to quality concerns, reduced delivery updates, and potential lawsuits.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Travere Therapeutics to Report Third Quarter 2025 Financial Results

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2025 financial results on Thursday, October 30, 2025, after the close of the U.S. financial markets. The Company...

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including a late-breaking poster, at the upcoming American Society of Nephrology (ASN) Kidney...

NVS Reports Positive Late-Stage Data on Kidney Disease Drug 

Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.

What Makes Travere (TVTX) a New Strong Buy Stock

Travere (TVTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings?

MIRM's Livmarli remains its dominant growth engine and is expected to have boosted its top line in the third quarter.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of...

TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA

Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.

Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?

Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Travere Therapeutics (TVTX) on Wednesday said that the U.S. Food and Drug Administration informed the company that it has waived the need for an advisory committee meeting regarding its application for Filspari in treating focal segmental glomerulosclerosis (FSGS).The FDA is expected to decide on the company’s application by January 13, 2026. If approved, Filspari would be the first medication indicated for FSGS, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250910301976/en/Travere-Therapeutics-Provides-Update-on-FDA-Advisory-Committee-Meeting-for-FILSPARI-sparsentan-in-FSGS">said</a>. FSGS is a rare and serious kidney disorder driven by proteinuria or protein leaks into the urine due to a breakdown of the normal filtration mechanism in the kidney. The disease leads to progressive kidney function loss and kidney failure and is estimated to affect more than 40,000 patients in the U.S., according to Travere. &nbsp;Shares of the company soared 16% in the pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TVTX">TVTX stock</a> stayed within ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.CEO Eric Dube said that the company is pleased with the progress of its new application for Filspari to date and is continuing preparation for a successful commercial launch in January, if approved.The company’s application is supported by data from mid-stage and late-stage studies where Filspari demonstrated rapid, superior, and sustained reductions in proteinuria when compared with the maximum labeled dose of the approved drug Irbesartan across adult and pediatric patients. The drug was also well-tolerated in the studies with a safety profile comparable to Irbesartan.Filspari is already approved by the FDA to slow kidney function decline in adults with IgA nephropathy, a chronic autoimmune kidney disease characterized by the abnormal accumulation of immunoglobulin A (IgA) antibodies in the kidneys' filtering units. The new application by the company seeks to expand its use to the treatment of FSGS as well.TVTX stock is up by 24% this year and by about 69% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bioxcel-stock-rises-pre-market-after-company-announces-positive-efficacy-data-for-agitation-drug-in-study/chwk7aERdub">BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Travere Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application

If approved, Filspari would be the first medication indicated for focal segmental glomerulosclerosis, a rare and serious kidney disorder driven by proteinuria, the company said. 

Equity

If approved, Filspari would be the first medication indicated for focal segmental glomerulosclerosis, a rare and serious kidney disorder driven by proteinuria, the company said. 


Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings

Although the revenue and EPS for Travere (TVTX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

TVTX
Travere Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TVTX News

TVTXTravere Therapeutics Inc